



NOVEMBER SEMINAR NOTICE

Presented by

Yale School of Medicine's, Department of Therapeutic Radiology

“Early Cancer Detection and Therapy Monitoring Via DNA Signatures in Blood”

Abhijit Patel, MD, PhD
Associate Professor of Therapeutic Radiology
Department of Therapeutic Radiology
Yale School of Medicine

Date: Thursday, November 14, 2019, 9:00AM
Location: Smilow LL505

Course Director/Host: Henry S. Park, MD, MPH

There is no corporate support for this activity

This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

Attending Physicians; Housestaff/Fellows; Medical Students; Nurses; PA's; Other

NEEDS ASSESSMENT

Circulating tumor DNA is showing great promise as a biomarker for noninvasive tumor genotyping, assessing treatment response, identifying residual or recurrent disease, and early cancer detection. Important technological advances are making these applications feasible. It is important for physicians to be aware of progress in this area, as clinical implementation for circulating DNA-based diagnostics appears to be growing.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to

1. Participants will learn about current and future clinical applications of circulating tumor DNA.
2. Participants will learn how ctDNA can be used as an early biomarker of immunotherapy response.

3. Participants will learn how next-generation DNA sequencing technologies are being adapted to quantify low-abundance ctDNA in blood.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Abhijit Patel, MD, PhD – AstraZeneca- research grant to Yale, Co-PI; Binary Genomics, Inc.- Equity, Founder; Patent applications/awards covering ctDNA technology- Intellectual Property, Inventor/Assignee; NuGEN Technologies – Honorarium/Stock Options, Scientific Advisor; Henry S. Park, MD, MPH – RadOncQuestions, LLC, Honorarium, Editor

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.